Drug Profile
Ozarelix
Alternative Names: D-63153; SPI-153Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc
- Developer AEterna Zentaris Inc; Assertio Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Gonadotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
- No development reported Endometriosis
- Discontinued Alzheimer's disease; Benign prostatic hyperplasia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in USA (IM, Injection)
- 11 Jun 2015 Phase-II development for prostate cancer is ongoing in the US and India
- 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc